A new anti-mesothelin antibody targets selectively the membrane-associated form

References

• Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 1994; 269:805-08; PMID:8288629
   PubMed Web of Science ®Google Scholar
• Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res Off J Am Assoc Cancer Res 2004; 10:3937-42; PMID:15217923; http://dx.doi.org/10.1158/1078-0432.CCR-03-0801
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6; PMID:7494563; http://dx.doi.org/10.1056/NEJM199601043340101
   PubMed Web of Science ®Google Scholar
• Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res Off J Am Assoc Cancer Res 2001; 7:3862-68; PMID:11751476
   PubMed Web of Science ®Google Scholar
• Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol AIMM Off Publ Soc Appl Immunohistochem 2005; 13:243-47; PMID:16082249; http://dx.doi.org/10.1097/01.pai.00000141545.36485.d6
   PubMed Web of Science ®Google Scholar
• Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen C, Yao Q. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008; 7:286-96; PMID:18281514; http://dx.doi.org/10.1158/1535-7163.MCT-07-0483
   PubMed Web of Science ®Google Scholar
• Yen MJ, Hsu C-Y, Mao T-L, Wu T-C, Roden R, Wang T-L, Shih I-M. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 2006; 12:827-31; PMID:16467095; http://dx.doi.org/10.1158/1078-0432.CCR-05-1397
   PubMed Web of Science ®Google Scholar
• Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I. Mesothelin expression in human lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2007; 13:1571-75; PMID:17332303; http://dx.doi.org/10.1158/1078-0432.CCR-06-2161
   PubMed Web of Science ®Google Scholar
• Muminova ZE, Strong TV, Shaw DR. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer 2004; 4:19; PMID:15140265; http://dx.doi.org/10.1186/1471-2407-4-19
   PubMed Web of Science ®Google Scholar
• Sapede C, Gauvrit A, Barbieux I, Padieu M, Cellerin L, Sagan C, Scherpereel A, Dabouis G, Grégoire M. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci 2008; 99:590-94; PMID:18167128; http://dx.doi.org/10.1111/j.1349-7006.2007.00715.x
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I. Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding. Cancer Res 2011; 71:5915-22; PMID:21775520; http://dx.doi.org/10.1158/0008-5472.CAN-11-0466
   PubMed Web of Science ®Google Scholar
• Bütikofer P, Malherbe T, Boschung M, Roditi I. GPI-anchored proteins: now you see ‘em, now you don't. FASEB J 2001; 15:545-8; PMID:11156970; http://dx.doi.org/10.1096/fj.00-0415hyp
   PubMed Web of Science ®Google Scholar
• Mayor S, Riezman H. Sorting GPI-anchored proteins. Nat Rev Mol Cell Biol 2004; 5:110-20; PMID:15040444; http://dx.doi.org/10.1038/nrm1309
   PubMed Web of Science ®Google Scholar
• Paulick MG, Bertozzi CR. The Glycosylphosphatidylinositol Anchor: A Complex Membrane-Anchoring Structure for Proteins. Biochemistry (Mosc) 2008; 47:6991-7000; PMID:18557633; http://dx.doi.org/10.1021/bi8006324
   Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157:220-33; PMID:19459844; http://dx.doi.org/10.1111/j.1476-5381.2009.00190.x
   PubMed Web of Science ®Google Scholar
• Ma J, Tang WK, Esser L, Pastan I, Xia D. Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights. J Biol Chem 2012; 287:33123-31; PMID:22787150; http://dx.doi.org/10.1074/jbc.M112.381756
   PubMed Web of Science ®Google Scholar
• Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res Off J Am Assoc Cancer Res 2005; 11:1545-50; PMID:15746059; http://dx.doi.org/10.1158/1078-0432.CCR-04-1939
   PubMed Web of Science ®Google Scholar
• Hollevoet K, Mason-Osann E, Liu X, Imhof-Jung S, Niederfellner G, Pastan I. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther 2014; 13:2040-49; PMID:24928849; http://dx.doi.org/10.1158/1535-7163.MCT-14-0089-T
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 2012; 11:517-25; PMID:22351743; http://dx.doi.org/10.1158/1535-7163.MCT-11-0454
   PubMed Web of Science ®Google Scholar
• de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol 2016; 40:14-23; PMID:26963132; http://dx.doi.org/10.1016/j.coi.2016.02.008
   PubMed Web of Science ®Google Scholar
• Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, Ho M. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther 2013; 12:416-26; PMID:23371858; http://dx.doi.org/10.1158/1535-7163.MCT-12-0731
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiang L, Hassan R, Pastan I. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A 2007; 104:17099-104; PMID:17940013; http://dx.doi.org/10.1073/pnas.0708101104
   PubMed Web of Science ®Google Scholar
• Awuah P, Bera TK, Folivi M, Chertov O, Pastan I. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin Targeting Recombinant Immunotoxins. Mol Cancer Ther molcanther 2016; 15(7):1648-55; PMID:27196771; http://dx.doi.org/10.1158/1535-7163.MCT-15-0863
   PubMed Web of Science ®Google Scholar
• Mapara MY, Pelot M, Zhao G, Swenson K, Pearson D, Sykes M. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 2001; 7:646-55; PMID:11787527; http://dx.doi.org/10.1053/bbmt.2001.v7.pm11787527
   PubMed Web of Science ®Google Scholar
• Hairul Bahara NH, Tye GJ, Choong YS, Ong EBB, Ismail A, Lim TS. Phage display antibodies for diagnostic applications. Biol J Int Assoc Biol Stand 2013; 41:209-16; PMID:23647952; http://dx.doi.org/10.1016/j.biologicals.2013.04.001
   Web of Science ®Google Scholar
• Moutel S, Vielemeyer O, Jin H, Divoux S, Benaroch P, Perez F. Fully in vitro selection of recombinant antibodies. Biotechnol J 2009; 4:38-43; PMID:19156724; http://dx.doi.org/10.1002/biot.200800246
   PubMedGoogle Scholar
• Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR. Conformations of immunoglobulin hypervariable regions. Nature 1989; 342:877-883; PMID:2687698; http://dx.doi.org/10.1038/342877a0
   PubMed Web of Science ®Google Scholar
• Wilson IA, Stanfield RL. Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol 1994; 4:857-67; PMID:7536111; http://dx.doi.org/10.1016/0959-440X(94)90267-4
   PubMed Web of Science ®Google Scholar
• Xu JL, Davis MM. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 2000; 13:37-45; PMID:10933393; http://dx.doi.org/10.1016/S1074-7613(00)00006-6
   PubMed Web of Science ®Google Scholar
• Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, et al. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Cancer Invest 2013; 31:43-50; PMID:23249166; http://dx.doi.org/10.3109/07357907.2012.749265
   PubMed Web of Science ®Google Scholar
• Cui A, Jin X-G, Zhai K, Tong Z-H, Shi H-Z. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open 2014; 4:e004145; PMID:24566531; http://dx.doi.org/10.1136/bmjopen-2013-004145
   PubMedGoogle Scholar
• Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. Dis Markers 2012; 32:123-31; PMID:22377706; http://dx.doi.org/10.1155/2012/430689
   PubMed Web of Science ®Google Scholar
• Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85:265-72; discussion 272; PMID:18154821; http://dx.doi.org/10.1016/j.athoracsur.2007.07.042
   PubMed Web of Science ®Google Scholar
• Wu X, Li D, Liu L, Liu B, Liang H, Yang B. Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer. Arch Gynecol Obstet 2014; 289:1309-14; PMID:24370956; http://dx.doi.org/10.1007/s00404-013-3128-x
   PubMed Web of Science ®Google Scholar
• Rooney IA, Heuser JE, Atkinson JP. GPI-anchored complement regulatory proteins in seminal plasma. An analysis of their physical condition and the mechanisms of their binding to exogenous cells. J Clin Invest 1996; 97:1675-86; PMID:8601633; http://dx.doi.org/10.1172/JCI118594
   PubMed Web of Science ®Google Scholar
• van Zanten TS, Cambi A, Koopman M, Joosten B, Figdor CG, Garcia-Parajo MF. Hotspots of GPI-anchored proteins and integrin nanoclusters function as nucleation sites for cell adhesion. Proc Natl Acad Sci U S A 2009; 106:18557-62; PMID:19850864; http://dx.doi.org/10.1073/pnas.0905217106
   PubMed Web of Science ®Google Scholar
• Ruiz M. Lefranc MP. Currents in Computational Molecular Biology. Tokyo: Universal Academy Press. Front Sci Ser 2000; 126-27
   Google Scholar
• Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 2014; 74:2907-12; PMID:24824231; http://dx.doi.org/10.1158/0008-5472.CAN-14-0337
   PubMed Web of Science ®Google Scholar
• Chang M-C, Chen Y-L, Chiang Y-C, Chen T-C, Tang Y-C, Chen C-A, Sun W-Z, Cheng W-F. Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator. Gene Ther 2016; 23:38-49; PMID:26262583; http://dx.doi.org/10.1038/gt.2015.85
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 2012; 11:517-25; PMID:22351743; http://dx.doi.org/10.1158/1535-7163.MCT-11-0454
   PubMed Web of Science ®Google Scholar
• O'Hara M, Stashwick C, Haas AR, Tanyi JL. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 2016; 8:449-60; PMID:26973126; http://dx.doi.org/10.2217/imt.16.4
   PubMed Web of Science ®Google Scholar
• Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 2013; 5:208ra147; PMID:24154601; http://dx.doi.org/10.1126/scitranslmed.3006941
   PubMed Web of Science ®Google Scholar
• Weldon JE, Skarzynski M, Therres JA, Ostovitz JR, Zhou H, Kreitman RJ, Pastan I. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A. Bioconjug Chem 2015; 26:1120-28; PMID:25997032; http://dx.doi.org/10.1021/acs.bioconjchem.5b00190
   PubMed Web of Science ®Google Scholar
• Zhang Y, Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res Off J Am Assoc Cancer Res 2008; 14:7981-86; PMID:19088013; http://dx.doi.org/10.1158/1078-0432.CCR-08-0324
   PubMed Web of Science ®Google Scholar
• Bradley JE, Chan JM, Hagood JS. Effect of the GPI anchor of human Thy-1 on antibody recognition and function. Lab Investig J Tech Methods Pathol 2013; 93:365-74; PMID:23358110; http://dx.doi.org/10.1038/labinvest.2012.178
   PubMed Web of Science ®Google Scholar
• Cardoso de Almeida ML, Turner MJ. The membrane form of variant surface glycoproteins of Trypanosoma brucei. Nature 1983; 302:349-52; PMID:6188057; http://dx.doi.org/10.1038/302349a0
   PubMed Web of Science ®Google Scholar
• Miller EN, Allan LM, Turner MJ. Topological analysis of antigenic determinants on a variant surface glycoprotein of Trypanosoma brucei. Mol Biochem Parasitol 1984; 13:67-81; PMID:6083452; http://dx.doi.org/10.1016/0166-6851(84)90102-6
   PubMed Web of Science ®Google Scholar
• Tomavo S, Dubremetz J-F, Schwarz RT. Structural analysis of glycosyl-phosphatidylinositol membrane anchor of the Toxoplasma gondii tachyzoite surface glycoprotein gp23. Biol Cell 1993; 78:155-62; PMID:8241958; http://dx.doi.org/10.1016/0248-4900(93)90126-Y
   PubMed Web of Science ®Google Scholar
• Barboni E, Rivero BP, George AJ, Martin SR, Renoup DV, Hounsell EF, Barber PC, Morris RJ. The glycophosphatidylinositol anchor affects the conformation of Thy-1 protein. J Cell Sci 1995; 108 ( Pt 2):487-97; PMID:7539435
   PubMed Web of Science ®Google Scholar
• Hale G. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology Int J Immunol Eng 1995; 1:175-87; PMID:9373346; http://dx.doi.org/10.1016/1380-2933(95)00017-8
   Web of Science ®Google Scholar
• Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates—A new wave of cancer drugs. Bioorg Med Chem Lett 2014; 24:5357-63; PMID:25455482; http://dx.doi.org/10.1016/j.bmcl.2014.10.021
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6:559-65; PMID:16794638; http://dx.doi.org/10.1038/nrc1891
   PubMed Web of Science ®Google Scholar
• Seidel UJE, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 2013; 4:76; PMID:23543707; http://dx.doi.org/10.3389/fimmu.2013.00076
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014; 6:261ra151; PMID:25378643; http://dx.doi.org/10.1126/scitranslmed.3010162
   PubMed Web of Science ®Google Scholar
• Morello A, Sadelain M, Adusumilli PS. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov 2016; 6:133-146; PMID:26503962; http://dx.doi.org/10.1158/2159-8290.CD-15-0583
   PubMed Web of Science ®Google Scholar
• Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222:581-97; PMID:1748994; http://dx.doi.org/10.1016/0022-2836(91)90498-U
   PubMed Web of Science ®Google Scholar
• Ng WC, Wong V, Muller B, Rawlin B, Brown EL. Prevention and treatment of influenza with hyperimmune bovine colostrum antibody. PlosOne 2010; e13622; PMID:21049034; http://dx.doi.org/10.1371/journal.pone.0013622
   Google Scholar